DB17850InvestigationalGene Therapies
TAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.
- Also known as
- BAX 888 · BAX-888 · SHP 654 · SHP-654 · SHP654
- Code names
- TAK-754
What you can answer from here — as of April 23, 2025
Which companies are running trials of TAK-754, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account